瑞舒伐他汀对2型糖尿病患者低密度脂蛋白胆固醇和超敏C反应蛋白的影响

摘要

目的 探讨瑞舒伐他汀对2型糖尿病患者低密度脂蛋白胆固醇(LDL-C)和高敏C反应蛋白(hsCRP)的影响.方法 将2型糖尿病患者随机分为A组、B组、C组,分别予以安慰剂、辛伐他汀(20 mg/d)和瑞舒伐他汀(10 mg/d)连续治疗3个月,于治疗前后分别测定患者低密度脂蛋白和超敏C反应蛋白水平.结果 B组、C组治疗后低密度脂蛋白和超敏C反应蛋白水平均低于同组治疗前水平(P＜0.05＝;C组治疗后低密度脂蛋白和超敏C反应蛋白水平均低于A组、B组治疗后水平(P＜0.05＝.结论 瑞舒伐他汀能降低2型糖尿病患者的低密度脂蛋白和超敏C反应蛋白水平且效果优于辛伐他汀,在预防2型糖尿病患者的心血管事件方面可能起到重要作用.%Objective To investigate the effects of rosuvastatin on low density lipoprotein cholesterol (LDL-C) and high sensitivity C - reactive protein (hs-CRP) in the patients with type 2 diabetes mellitus(T2DM). Methods The patients with T2DM were divided into group A, B and C and given placebo, si its vast at in 20 nig and rosuvastatin I 0 rag once a day respectively for 3 months. LDL - C and hs - CRP were measured before and after treatment. Result!! LDL - C and hs - CR.P after treatment in the group B and C was lower than those before treatment ( P < 0. 05). LDL - C and hs-CRP after treatment in the group C was lower than those in the group A and B (P<0.05). Conclusion Rosuvastatin can reduce both hs-CRP and LDL-C levels in type 2 diabetic patients with better effects than simvastatin and plays an important role in preventing the cardiovascular events.